SequelSEC

Bicara Therapeutics Inc. BCAX

Pharmaceutical Preparations · CIK 0002023658 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2026-06-30
Operating income
-$59.95M
Fiscal year ended 2026-06-30
Free cash flow
-$44.27M
Fiscal year ended 2026-06-30

Bicara Therapeutics Inc. (BCAX) reported net income of -$55.44M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Bicara Therapeutics Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Bicara Therapeutics Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$59.95MUnavailable-$41.12M-$40.68MUnavailableUnavailable-$26.64M-$20.63MUnavailableUnavailable
Net income-$55.44MUnavailable-$37.39M-$36.33MUnavailableUnavailable-$20.96M-$17.48MUnavailableUnavailable
Research & developmentUnavailableUnavailableUnavailable$33.00MUnavailableUnavailable$19.90M$15.90MUnavailableUnavailable
Weighted-average diluted sharesshares 67.93MUnavailableUnavailableshares 54.56MUnavailableUnavailableUnavailableshares 10.90MUnavailableUnavailable
Pretax income-$55.38MUnavailable-$37.33M-$36.29MUnavailableUnavailable-$20.77M-$17.48MUnavailableUnavailable
Income tax expense$61.00KUnavailable$53.00K$40.00KUnavailableUnavailable$186.00K$0UnavailableUnavailable
Diluted EPS$-0.82UnavailableUnavailable$-0.67UnavailableUnavailableUnavailable$-1.60UnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$14.18MUnavailable$8.13M$7.70MUnavailableUnavailable$6.75M$4.76MUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Bicara Therapeutics Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$96.60MUnavailable$96.68M$171.67MUnavailableUnavailable$489.71M$520.76MUnavailableUnavailable
Total assets$512.24MUnavailable$430.99M$424.69MUnavailableUnavailable$510.00M$524.17MUnavailableUnavailable
Current assets$503.82MUnavailable$422.05M$297.37MUnavailableUnavailable$502.53M$521.51MUnavailableUnavailable
Total liabilities$43.48MUnavailable$29.54M$21.91MUnavailableUnavailable$18.12M$14.62MUnavailableUnavailable
Current liabilities$43.48MUnavailable$28.95M$21.03MUnavailableUnavailable$17.99M$14.48MUnavailableUnavailable
Total equity incl. NCI$468.77MUnavailable$401.45M$402.78MUnavailableUnavailable$491.88M$509.56MUnavailableUnavailable
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$0$0UnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

Bicara Therapeutics Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$44.21MUnavailable-$23.89M-$29.25MUnavailableUnavailable-$30.03M-$17.22MUnavailableUnavailable
Capital expenditures$60.00KUnavailable$238.00K$42.00KUnavailableUnavailable$40.00K$8.00KUnavailableUnavailable
Investing cash flow-$184.99MUnavailable-$82.33M-$236.12MUnavailableUnavailable-$40.00K-$8.00KUnavailableUnavailable
Financing cash flow$2.33MUnavailable$31.23M$436.00KUnavailableUnavailable-$975.00K$334.14MUnavailableUnavailable
Net change in cash-$226.86MUnavailable-$74.99M-$264.93MUnavailableUnavailable-$31.05M$316.90MUnavailableUnavailable
Stock-based compensation$8.24MUnavailable$4.45M$3.61MUnavailableUnavailable$3.18M$2.03MUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Bicara Therapeutics Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow-$44.27MUnavailable-$24.12M-$29.29MUnavailableUnavailable-$30.07M-$17.23MUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio11.59xUnavailable14.58x14.14xUnavailableUnavailable27.93x36.01xUnavailableUnavailable
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BCAX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

10 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2026-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2026-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2024-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2024-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.